Methods and systems for treating cell proliferation disorders

Patent metadata

Field	Value
Publication number	US-9358292-B2
Application number	US-93565507-A
Country	US
Kind code	B2
Filing date	Nov 6, 2007
Priority date	Apr 8, 2007
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

Methods for the treatment of a cell proliferation disorder in a subject, involving:
(1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

First claim

The invention claimed is:

1. A method for treating cancer in a subject, comprising:
(1) administering to the subject a pharmaceutical agent comprising at least one of 8-methoxypsoralen (8-MOP) and 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) that causes a cellular change when activated;
(2) administering to the subject at least one energy modulation agent comprising a phosphorescent agent that, upon reception of X-ray energy, emits light that activates the pharmaceutical agent;
wherein the at least one energy modulation agent and the pharmaceutical agent are independent and separately movable from each other; and
(3) applying the X-ray energy from an X-ray energy source to the subject,
and wherein the at least one energy modulation agent activates the pharmaceutical agent in situ with said light emitted from the phosphorescent agent, thus causing the cellular change to occur, wherein said cellular change treats by inducing apoptosis in cancer cells.

2. The method of claim 1 , wherein the pharmaceutical agent has affinity for a cancer cell.

3. The method of claim 1 , wherein the pharmaceutical agent is capable of being absorbed by a cancer cell.

4. The method of claim 1 , wherein the pharmaceutical agent causes an auto-vaccine effect in the subject.

5. The method of claim 1 , wherein the pharmaceutical agent is activated by one or more sequential single photon absorption events.

6. The method of claim 1 , wherein the pharmaceutical agent is contained within a photocage, wherein upon exposure to said X-ray energy source, the photocage disassociates, rendering the pharmaceutical agent available.

7. A method for treating cancer in a subject, comprising:
(1) administering to the subject a pharmaceutical agent comprising at least one of 8-methoxypsoralen (8-MOP) and 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) that causes a cellular change when activated; and
(2) administering to the subject at least one energy modulation agent comprising a phosphorescent agent and applying an initiation energy from an initiation energy source to the subject, wherein the initiation energy is X-ray energy,
wherein the at least one energy modulation agent and the pharmaceutical agent are independent and separately movable from each other,
wherein the at least one energy modulation agent receives the X-ray energy and converts the applied X-ray energy to UV-A or visible energy, which then activates the pharmaceutical agent in situ,

thus causing the cellular change to occur, wherein said cellular change treats cancer, wherein the treatment of cancer occurs by inducing apoptosis in cancer cells.

8. The method of claim 7 , wherein the pharmaceutical agent has affinity for a cancer cell.

9. The method of claim 7 , wherein the pharmaceutical agent is capable of being absorbed by a cancer cell.

10. The method of claim 7 , wherein the pharmaceutical agent causes an auto-vaccine effect in the subject.

11. The method of claim 7 , further comprising a blocking agent, wherein the blocking agent is capable of blocking uptake of the pharmaceutical agent prior to its activation.

12. The method of claim 11 , wherein the blocking agent is capable of slowing down mitosis in non-cancer cells while allowing cancer cells to maintain an abnormal rate of mitosis.

13. The method of claim 7 , wherein the pharmaceutical agent is contained within a photocage, wherein upon exposure to said UV-A or visible energy, the photocage disassociates, rendering the pharmaceutical agent available.

14. The method of claim 7 , wherein the pharmaceutical agent is activated by one or more sequential single photon absorption events.

15. A method for treating cancer in a subject, comprising:
(1) administering to the subject a pharmaceutical agent comprising at least one of 8-methoxypsoralen (8-MOP) and 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) that causes a cellular change when activated;
(2) administering to the subject at least one energy modulation agent comprising a phosphorescent agent that converts an X-ray energy to light that activates the pharmaceutical agent;
wherein the at least one energy modulation agent and the pharmaceutical agent are independent and separately movable from each other; and
(3) indirectly applying the X-ray energy from an X-ray energy source to the pharmaceutical agent within the subject, wherein the energy that activates the pharmaceutical agent activates the pharmaceutical agent in situ with said light emitted from the phosphorescent agent,
wherein the at least one energy modulation agent receives the X-ray energy and re-emits light,
thus causing the cellular change to occur, wherein said cellular change treats cancer, wherein the treatment of cancer occurs by inducing apoptosis in cancer cells.

16. The method according to claim 15 , wherein the pharmaceutical agent causes an auto-vaccine effect in the subject.

17. The method of claim 15 , wherein the pharmaceutical agent is contained within a photocage, wherein upon exposure to said X-ray energy, the photocage disassociates, rendering the pharmaceutical agent available.

18. The method of claim 15 , wherein the pharmaceutical agent has affinity for a cancer cell.

19. The method of claim 15 , wherein the pharmaceutical agent is capable of being preferentially absorbed by a cancer cell.

20. The method of claim 15 , wherein the pharmaceutical agent is activated by one or more sequential single photon absorption events.

21. The method of claim 1 , wherein the cancer is breast cancer, prostate cancer, of skin cancer.

22. The method of claim 7 , wherein the cancer is breast cancer, prostate cancer, of skin cancer.

23. The method of claim 15 , wherein the cancer is breast cancer, prostate cancer, of skin cancer.

Assignees

• Bourke Jr Frederic A
• Immunolight Llc

Inventors

• Bourke Jr Frederic A

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title